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Low-Gradient, Low-Ejection
Fraction Aortic Stenosis
What We Know and What We Do Not Know*
Blase A. Carabello, MD†‡
Houston, Texas
What We Know
It is generally held that outcome for patients with valvular
heart disease is largely determined by the contractility of the
left and/or right ventricles. This innate force generation
capability might become compromised when chronic severe
hemodynamic overload injures the myocardium, impairing
function and prognosis. In aortic stenosis (AS), impaired left
ventricular (LV) ejection is in part predicated on reduced
contractility and also upon excess afterload imposed by the
stenotic valve as it causes obstruction to outflow (1–4). The
property that dominates—excess afterload versus reduced
contractility—in a given patient determines prognosis (2).
See page 552
When afterload excess attended by a large transvalvular
gradient is dominant, ejection fraction (EF) can return
completely to normal after aortic valve replacement, and
improvement in symptoms is striking (2,5). It is fair to add
that many patients with a normal EF still have modest
systolic dysfunction at the sarcomere level (6). This occurs as
LV hypertrophy, by adding sarcomeres in parallel, allows
normal LV systolic thickening despite reduced systolic
sarcomere shortening. Still, aortic valve replacement (AVR)
causes a large decrease in afterload, and impaired ejection
improves almost immediately in the AS patient with a large
gradient and a large preoperative afterload (5).
However, when impaired contractility is the major cause
of impaired LV ejection, the prognosis is much worse
(2,7–10). In such cases, the weakened ventricle produces a
small stroke volume, which in turn produces a low trans-
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tients, approaching 35% in some series. Prognosis is im-
proved if patients show a substantial (at least 20%) increase
in stroke volume during infusion of a positive inotrope such
as dobutamine (11,12). By contrast, patients with ultra-low
mean gradients (20 mm Hg) have a very poor prognosis,
especially when impaired LV function is due to coronary
disease and extensive myocardial infarction (9,10). We also
know that operative outcome is reduced if the inserted
prosthesis has a substantial residual gradient (8). The
aforementioned findings are intuitive and logical. If the LV
is extensively scarred by coronary disease, aortic valve
replacement would be expected to be ineffective. Likewise,
patients with the lowest gradients likely have the most
impaired ventricles, and any residual gradient after AVR
would detract from the hemodynamic benefit of the valve
replacement. Or looking at the problem from another angle,
a very low pre-operative gradient offers little chance for
reduction in total LV pressure demand postoperatively, and
improvement in symptoms and LV function is likely to be
curtailed.
What We Do Not Know
Thus we have learned much about the low-EF, low-
gradient patient, but much is left unknown. As noted in the
preceding text, detection of inotropic reserve is very useful in
assessing the risk of AVR. Operative risk is approximately
10% for those with inotropic reserve versus over 30% for
those patients without inotropic reserve (12). Remarkably
however, for those inotropic-negative patients who survive
AVR, improvement in EF can be as robust as for patients
that did have inotropic reserve (13). A reasonable hypothesis
that follows is that inotropic reserve helps get the patient
through the surgical stress of AVR, but once that hurdle is
successfully overcome, other myocardial changes allow for
improved LV function after a relatively non-stenotic valve is
implanted. How and why the LV without inotropic reserve
recovers after AVR will be crucial in determining which
inotropic reserve-negative patients will and will not benefit
from AVR.
For those patients who have inotropic reserve, 2 different
responses have been observed. In some patients, increased
stroke volume increases the gradient, and valve area remains
small, as would be expected from a fixed obstruction to
outflow. In others, the increase in stroke volume causes little
increase in transvalvular gradient, and calculated valve area
increases substantially. Such patients are believed to have
aortic “pseudo” stenosis, wherein a LV weakened by an
independent cardiomyopathy is unable to generate enough
force to open a relatively pliable and only moderately
stenotic valve (14,15). When increased inotropy is applied,
the valve opens more widely, and calculated valve area
increases. It has generally been assumed that AVR would
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561not benefit such patients, because AS was not the major
cause of patient heart failure to begin with. Accordingly, few
such patients receive an AVR. Of interest are data (few as
they might be) from the TOPAS (True or Pseudo-Severe
Aortic Stenosis) registry where 4 of 5 patients with pseudo
stenosis had a good outcome with AVR (16,17). It is
possible that in such patients, the removal of only mild-to-
moderate obstruction to outflow is beneficial to such se-
verely compromised ventricles. Obviously, far more data are
required to address this issue before AVR for pseudo AS
could be realistically considered.
The Current Study
From the foregoing, the possible utility of avoiding standard
open heart surgery in such ill patients—especially inotropic-
negative low-EF, low-gradient patients—and replacing it
with a transcatheter approach (transcatheter aortic valve
replacement [TAVR]) has obvious appeal. That the cur-
rently available transcatheter valves have an excellent hemo-
dynamic profile enhances the possibility of success. Com-
parison with other reports is fraught with difficulty, but such
comparisons are inevitable. Thus, the paper by Lauten et al.
(18) in this issue of JACC: Cardiovascular Interventions is of
special interest. In their report of data from the German
Transcatheter Aortic Valve Interventions Registry, the out-
come of 149 patients undergoing TAVR with low-gradient,
low-EF (mean gradient 40 mm Hg, EF 0.40). AS was
compared with 1,153 patients with better LV function. The
1-year mortality in the current study, was 37% for the
low-gradient, low-EF group, compared with 18% for pa-
tients with better LV function. The low EF group com-
pared favorably with the 30% 1-year mortality in the TAVR
arm of the PARTNER Cohort B (Placement of AoRTic
TraNscathetER Valve—Cohort B) study of inoperable AS
patients (19). Although PARTNER patients had serious
comorbidities that rendered them inoperable, average EF
was 0.54 compared with 0.38 in the current study; the mean
gradient in the PARTNER study was greater—45 mm Hg
versus 31 mm Hg in the current study. By contrast, in the
study by Monin et al. (12) of low-gradient, low-EF patients,
EF was 0.30 and mean gradient was 29 mm Hg. One-year
mortality was approximately 15% for patients with inotropic
reserve and approximately double that in the absence of
inotropic reserve. In the current study, inotropic reserve was
evaluated but not reported so that comparison is difficult.
Thus the major question of whether TAVR is superior to
standard AVR or even to “medical” therapy in low-gradient,
low-EF AS patients cannot be answered from the current
data, although the study is encouraging. Especially left in
question are patients with the worst prognosis, those with
mean gradients of 20 mm Hg and EF of 0.30. Cleary a
randomized trial in this group of patients will be needed tosee whether TAVR is superior to either “medical” therapy or
standard surgery in this group.
Conclusions
Since its description over 30 years ago, we have learned
much about the syndrome of low-EF, low-gradient AS. We
know that the presence of a relatively high mean gradient,
20 mm Hg, combined with a positive inotropic response
portends a relatively good prognosis, whereas the presence
of postoperative patient-prosthetic mismatch indicates a
poorer prognosis. We still don’t know why some patients
without inotropic reserve improve anyway or whether some
patients with pseudo AS might also benefit and whether
TAVR might be superior to standard AVR for such
patients. The study by Lauten et al. (18) clearly demon-
strates that TAVR is feasible in such patients and paves the
way for a randomized clinical trial of TAVR versus medical
therapy or TAVR versus surgical therapy.
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